Rhumbline Advisers Trims Stock Position in Qiagen (NYSE:QGEN)

Rhumbline Advisers cut its holdings in shares of Qiagen (NYSE:QGEN) by 5.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 194,303 shares of the company’s stock after selling 11,088 shares during the quarter. Rhumbline Advisers owned about 0.09% of Qiagen worth $7,801,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in shares of Qiagen by 7,684.0% in the 1st quarter. GAMMA Investing LLC now owns 118,161 shares of the company’s stock worth $4,744,000 after purchasing an additional 116,643 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Qiagen in the 4th quarter worth about $202,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Qiagen in the 4th quarter worth about $95,746,000. Forum Financial Management LP purchased a new position in shares of Qiagen in the 4th quarter worth about $221,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Qiagen in the fourth quarter valued at about $216,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Robert W. Baird increased their target price on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Redburn Atlantic lowered Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Finally, Wall Street Zen upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. Seven research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus price target of $48.42.

Qiagen Price Performance

Shares of NYSE QGEN opened at $46.24 on Wednesday. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The business has a 50 day moving average price of $42.50 and a two-hundred day moving average price of $42.12. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The firm has a market cap of $10.28 billion, a PE ratio of 128.76, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.44 EPS. Sell-side analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.